Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03596866
Title An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib (ALTA-3)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Ariad Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Brigatinib

Alectinib

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST